TW200716094A - Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor - Google Patents

Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Info

Publication number
TW200716094A
TW200716094A TW095114529A TW95114529A TW200716094A TW 200716094 A TW200716094 A TW 200716094A TW 095114529 A TW095114529 A TW 095114529A TW 95114529 A TW95114529 A TW 95114529A TW 200716094 A TW200716094 A TW 200716094A
Authority
TW
Taiwan
Prior art keywords
methods
pharmaceutical compositions
aromatase inhibitor
combination
phenyl
Prior art date
Application number
TW095114529A
Other languages
English (en)
Chinese (zh)
Inventor
Madelyn Curto
Melanie Sisson
Andrew George Lee
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200716094A publication Critical patent/TW200716094A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095114529A 2005-04-25 2006-04-24 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor TW200716094A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67480705P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
TW200716094A true TW200716094A (en) 2007-05-01

Family

ID=36693972

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114529A TW200716094A (en) 2005-04-25 2006-04-24 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Country Status (6)

Country Link
EP (1) EP1937251A2 (fr)
JP (1) JP2006306872A (fr)
AR (1) AR054258A1 (fr)
CA (1) CA2605796A1 (fr)
TW (1) TW200716094A (fr)
WO (1) WO2006114702A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2034984A4 (fr) 2006-06-02 2013-03-06 Pear Tree Women S Health Care Procédé de traitement de la vaginite atrophique
EP2070943A1 (fr) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Procédé de préparation des 6-Alkylidenandrost-1,4-dien-3-ones
WO2011002096A1 (fr) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Composé de marquage pour pet
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme
US11459617B2 (en) 2016-04-29 2022-10-04 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
AU2001289865B2 (en) * 2000-09-08 2007-03-01 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
WO2003017974A1 (fr) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Methode de traitement des troubles gynecologiques benins et trousse pharmaceutique destinee a etre utilisee dans ladite methode
WO2003032961A2 (fr) * 2001-10-10 2003-04-24 Pharmacia Italia Spa Procedes de prevention et de traitement de la deperdition osseuse avec des composes steroides
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
AU2005300315A1 (en) * 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Also Published As

Publication number Publication date
EP1937251A2 (fr) 2008-07-02
CA2605796A1 (fr) 2006-11-02
AR054258A1 (es) 2007-06-13
WO2006114702A3 (fr) 2007-01-04
JP2006306872A (ja) 2006-11-09
WO2006114702A2 (fr) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE504565T1 (de) Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
JP2010521483A5 (fr)
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
NZ593593A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
UA86957C2 (ru) Производные азепиноиндола в качестве фармацевтического средства
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TW200716094A (en) Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2409741A1 (fr) Inhibiteurs de production de tnf-.alpha.
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
ATE384058T1 (de) Thiazolderivate
WO2020115555A3 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
ATE502924T1 (de) Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden